5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Aptamers market is segmented by Type (Nucleic Acid, Peptide), Application, and Geography
Fastest Growing Market:
Advancements in aptamer development technologies, increasing R&D expenditure, and the rising number of companies investing in this market are some of the key driving factors responsible for the growth of Aptamers market. Numerous advantages offered by these small molecules, in comparison to established antibodies, have also led to higher demand for these molecules across a diverse range of medical applications. They are chemically synthesized, which eliminates batch-to-batch variation and demands less time for development. Along with this, continuous advancement in technologies is expected to stimulate growth.
However, many aptamers have failed to meet the requisite safety and efficacy standards in clinical studies. Thus, companies had to terminate their clinical investigation during late-stage clinical studies. This factor is likely to affect the growth of this market negatively. In addition, other factors, such as low awareness about these technologies in middle- and low-income countries and inadequate regulatory structure, may hamper the overall growth.
Aptamers are short, single-stranded DNA or RNA (ssDNA or ssRNA) molecules, which can selectively bind to a specific target, including peptides, proteins, small molecules, carbohydrates, toxins, and even live cells. Aptamers assume various shapes, owing to their tendency to form helices or single-stranded loops. These molecules are extremely versatile and are used to bind targets with high specificity and selectivity.
|Research and Development|
Report scope can be customized per your requirements. Click here.
Appropriate diagnosis is the most crucial factor for the treatment of diseases, especially the viral diseases. Over the past few years, aptamer technology has observed a significant rise in its demand and usage all across the world. It has been used in a wide range of diagnostic as well as therapeutic applications; several strategies are currently being explored, in a definitive or conclusive way, using aptamers against virus proteins. From a diagnostic point of view, aptamers are presently being designed as a bio-recognition element in a variety of diagnostic systems in order to detect viral proteins, either in the blood (serum or plasma) or in the infected cells.
To understand key trends, Download Sample Report
The North America region dominates the aptamers market due to rapid technological advancements and high investment and funding to support the development of aptamers. The United States has been the hub of all major R&D activities related to aptamers. The first aptamer therapeutic product ‘’Macugen’’ was approved in 2004 by the US FDA (United States Food and Drugs Administration).
In the country, R&D happens to be the most active area of application of aptamers. A significant proportion of demand is seen in research applications, which is also responsible for generating revenues in the market. Furthermore, the growing acceptance of personalized medicine is also one of the major factors driving the growth of the market. Aptamers have evolved rapidly in the past ten years, and aptamers have targeted a range of molecules involved in tumor progression and metastasis, present at different sites.
To understand geography trends, Download Sample Report.
The global aptamers market is highly competitive and consists of a number of major players. Companies, like AM Biotechnologies, LLC, Aptagen, LLC, Aptamer Sciences, Inc., Aptamer Group, Aptus Biotech S.L., Base Pair Biotechnologies, Inc., NOXXON Pharma, SomaLogic Inc., TriLink BioTechnologies, Inc., and Vivonics, Inc., among others, hold the substantial share in the aptamers market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Advantages of Aptamers Compared to Antibodies
4.2.2 Advancements in the Field of Aptamer Technologies
4.2.3 Growing Investment by Major Companies
4.3 Market Restraints
4.3.1 Unfavorable Pharmacokinetic Properties of Aptamers
4.3.2 Issues Regarding Aptamer Development
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1.1 Nucleic Acid
5.2.3 Research and Development
5.2.4 Other Applications
5.3.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.3.4 Middle-East & Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle-East & Africa
5.3.5 South America
220.127.116.11 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AM Biotechnologies, LLC
6.1.2 Aptagen, LLC
6.1.3 Aptamer Sciences, Inc.
6.1.4 Aptamer Group
6.1.5 Aptus Biotech S.L.
6.1.6 Base Pair Biotechnologies, Inc.
6.1.7 NOXXON Pharma
6.1.8 SomaLogic Inc.
6.1.9 Baush Health
6.1.10 Maravai Lifesciences (Trilink Biotechnologies)
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments